Evidence map›Paper›PMID 18466114›Full record

ArticleThe Biochemical journal2008

Opioid and chemokine receptor heterodimers: arranged marriages or dangerous liaisons?

Terence E Hébert

Abstract readComment
PubMed Publisher
In one paragraph

Article in The Biochemical journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Terence E HébertDepartment of Pharmacology and Therapeutics, Faculty of Medicine, 13th floor, Room 1303, McIntyre Medical Sciences Building, 3655 Promenade Sir William Osler, Montreal, QC, Canada, H3G 1Y6. terence.hebert@mcgill.ca

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Heterodimerization of GPCRs (G-protein-coupled receptors) has begun to be appreciated as a rich new vein for drug discovery. The possibility of developing modulators for different GPCRs which work at allosteric sites other than the ligand-binding site is not new, but the notion of using a dimeric receptor partner as the target for this intervention has not yet percolated into the broader industrial community. In the present article, I discuss this notion in the context of the heterodimeric delta-opioid receptor-CXCR2 chemokine receptor dimer identified by Parenty et al., in this issue of the Biochemical Journal.

Indexed as

Protein Structure, QuaternaryReceptors, Interleukin-8BDimerizationHumansReceptors, Opioid, deltaRecombinant Fusion ProteinsReceptors, Interleukin-8BReceptors, Opioid, deltaRecombinant Fusion Proteins

Identifiers

PMID18466114

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.